Related Experiment Videos
Urinary glycylprolyl dipeptidyl aminopeptidase (GP-DAP) in insulin-dependent diabetic patients
O Nukada1, M Kobayashi, T Moriwake
1Department of Pediatrics, Okayama University, School of Medicine, Japan.
Insights
Urinary glycylprolyl dipeptidyl aminopeptidase (GP-DAP) may indicate diabetic nephropathy in children. Increased GP-DAP levels correlate with poor metabolic control, suggesting its potential as a biomarker.
Area of Science:
- Pediatric Endocrinology
- Nephrology
- Metabolic Disorders
Background:
- Diabetic nephropathy is a serious complication of insulin-dependent diabetes.
- Early detection of kidney damage in diabetic children is crucial.
- Biomarkers for diabetic nephropathy are actively sought.
Purpose of the Study:
- To investigate urinary glycylprolyl dipeptidyl aminopeptidase (GP-DAP) concentrations in children with insulin-dependent diabetes.
- To assess the correlation of urinary GP-DAP with diabetic nephropathy and metabolic control.
- To evaluate GP-DAP as a potential biomarker for diabetic nephropathy.
Main Methods:
- Measured urinary GP-DAP concentrations in 36 children (aged 4-18 years) with insulin-dependent diabetes.
- Assessed duration of diabetes (1 month to 14 years).
- Correlated urinary GP-DAP with plasma fructosamine and presence of microalbuminuria.
Main Results:
- Abnormal urinary GP-DAP concentrations were observed in 19 out of 36 patients.
- Increased urinary GP-DAP was found in 12 patients without microalbuminuria.
- A significant positive correlation was found between urinary GP-DAP and plasma fructosamine (r = 0.52, p < 0.001).
Conclusions:
- Urinary GP-DAP may serve as a potential marker for diabetic nephropathy in children.
- Elevated urinary GP-DAP concentrations could also reflect poor metabolic control.
- Further longitudinal studies are necessary to confirm the clinical utility of urinary GP-DAP.
Abstract:
Urinary glycylprolyl dipeptidyl aminopeptidase (GP-DAP) concentrations were determined in 36 insulin-dependent diabetic children aged 4-18 years with a duration of diabetes ranging from 1 month to 14 years. Abnormal urinary GP-DAP concentrations were found in 19 of the 36 patients. Twelve of 27 patients without microalbuminuria also had increased urinary concentrations of GP-DAP. There was a significant correlation between urinary GP-DAP and plasma fructosamine (r = 0.52, p < 0.001). Our data suggest that urinary GP-DAP may be used as a marker for diabetic nephropathy. However, there is also a possibility that increased urinary GP-DAP concentrations are functionally related to poor metabolic control. Longitudinal studies are needed to establish the clinical usefulness of urinary GP-DAP.